Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 4,244 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Obesity, Overweight, or Chronic Weight Management
Interventions: Aleniglipron or Placebo, Aleniglipron; Drug
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 39
States / cities: Phoenix, Arizona • Anaheim, California • Los Angeles, California + 33 more

Conditions: Anesthesia, Propofol Adverse Reaction, Etomidate Adverse Reaction, Anesthesia Complication, Anesthesia; Adverse Effect, Anesthesia; Reaction
Interventions: Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7); Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions: peginesatide, Epoetin Alfa; Drug
Lead sponsor: Affymax; Industry
Eligibility: 18 Years and older
Enrollment: 803 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 89
States / cities: Paragould, Arkansas • Fairfield, California • Granada Hills, California + 76 more

Conditions: Acne Vulgaris
Interventions: Adapalene, Differin®, Placebo; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 20
States / cities: Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 15 more

Conditions: Cocaine Dependence
Interventions: Clavulanic Acid, Placebo; Drug · Other
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Nausea and Vomitting
Interventions: TAK-951, TAK-951 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Sickle Cell Disease
Interventions: IW-1701, Placebo; Drug
Lead sponsor: Cyclerion Therapeutics; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 30
States / cities: Orange, California • Washington D.C., District of Columbia • Aventura, Florida + 23 more

Conditions: GI Health
Interventions: Active GI Health Product 1, Placebo GI Health Control; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Sleep, Pain, Depression, Anxiety
Interventions: Placebo Control Form 1 Capsules, Health Active Study Product 1.1 Capsules, Health Active Study Product 1.2 Capsules, Health Active Study Product 1.3 Capsules; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 1,494 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Chronic Constipation, Functional Constipation
Interventions: Placebo Capsule, YKP10811 Drug Product Capsule; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Colitis, Crohn's Disease, Inflammatory Bowel Disease
Interventions: Immunologic Monitoring; Other
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: COVID-19, Coronavirus, SARS-CoV-2
Interventions: pathogen reduced SARS-CoV-2 convalescent plasma, Placebo; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 974 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 26
States / cities: Little Rock, Arkansas • La Jolla, California • Aurora, Colorado + 22 more

Conditions: Diabetes Mellitus Type 2
Interventions: PF-07081532, Placebo, Clopidogrel; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Anaheim, California • South Miami, Florida

Conditions: Myelofibrosis With Myeloid Metaplasia, Myeloid Metaplasia, Myelofibrosis
Interventions: Pomalidomide, Prednisone, Placebo to pomalidomide, Placebo to prednisone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 6
States / cities: Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more

Conditions: Cocaine Dependence
Interventions: cocaine hydrochloride, exenatide, placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Scleroderma, Systemic
Interventions: Peripheral Blood Stem Cells, Cyclophosphamide, Mesna, rATG, Methylprednisolone, Filgrastim, Fludarabine; Biological · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 17 Years to 60 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Retinitis Pigmentosa
Interventions: N-acetylcysteine, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 24
States / cities: Davis, California • Los Angeles, California • San Francisco, California + 21 more

Conditions: Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions: Avacopan, Placebo, Standard of Care; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2036
U.S. locations: 62
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Surprise, Arizona + 57 more

Conditions: Diabetic Foot Ulcer, Infection
Interventions: PluroGel N, PluroGel; Drug
Lead sponsor: PluroGen Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Phoenix, Arizona • Los Angeles, California • Oakland, California + 8 more

Conditions: Essential Tremor
Interventions: Perampanel, Placebo; Drug
Lead sponsor: VA Greater Los Angeles Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, PF-04937319 10 mg, PF-04937319 50 mg, PF-04937319 100 mg, Glimepiride; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 23
States / cities: Roseville, California • San Diego, California • Walnut Creek, California + 17 more

Conditions: CLN7
Interventions: AAV9/CLN7; Genetic
Lead sponsor: Benjamin Greenberg; Other
Eligibility: 1 Year to 18 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Food Allergy
Interventions: FAHF-2 (TM); Drug
Lead sponsor: Li, Xiu-Min, M.D.; Individual
Eligibility: 12 Years to 45 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Little Rock, Arkansas • New York, New York

Conditions: Interstitial Cystitis/Painful Bladder Syndrome, Myofascial Pelvic Pain
Interventions: Metoprolol Tartrate Oral Tablet, Placebo Oral Tablet, No intervention- observational sub-study; Drug · Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Evanston, Illinois • Richmond, Virginia

Search by objective public record fields.

A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

Propofol and Etomidate Admixtures Comparisons Trial (PEAC Trial)

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris

Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid

A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)

A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)

Radicle GI Health™ RFY: A Study Assessing the Impact of DAO Supplementation on Gastrointestinal and Other Histamine Intolerance Symptoms

Radicle Health1: A Study of Health and Wellness Formulations and Their Effects on Overall Health

A Phase 2 Study to Evaluate Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation

NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease

Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults

Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia

GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration

Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial

Oral N-acetylcysteine for Retinitis Pigmentosa

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Topical PluroGel N for the Treatment of Mildly Infected Diabetic Foot Ulcers

An Efficacy/Safety Study of Perampanel for Reducing Essential Tremor

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

Study for the Treatment for CLN7 Disease

Therapeutic Effect of Chinese Herbal Medicine on Food Allergy

Interstitial Cystitis: Examination of the Central Autonomic Network